Hyperlipidemia denials in California external review
In the California DMHC record, independent physician reviewers decided 236 published external-review cases involving hyperlipidemiaand overturned the plan’s denial in 38.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for hyperlipidemia
| Treatment | Decisions | Overturned |
|---|---|---|
| Advanced Lipoprotein Testing | 29 | 3.4% |
| Repatha | 23 | 43.5% |
| Wegovy | 22 | 95.5% |
| Zepbound | 20 | 95% |
| Repatha Sureclick | 17 | 52.9% |
| Praluent | 14 | 14.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 161 | 51.6% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 75 | 10.7% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound solution auto-injector. The submitted documentation supports the medical necessity of the requested medication. The U.S. Food and Drug Administration (FDA) approves the use of Zepbound (tirzepatide) injection for chronic weight management in adults with obesity, defined as a BMI of 30 kg/m² or greater, or who are overweight, defined as a body mass index (BMI) of 27 kg/m² or greater, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol for use in addition to a reduced calorie diet and increased physical activity. Anti-obesity medications, when combined with lifestyle intervention, produce larger weight losses than behavioral treatment alone.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for WeGovy 2.4 mg auto-injection. A review of the record indicates that the patient has been diagnosed with type 2 diabetes, hyperlipidemia, and obesity. The provider noted the patient has been undergoing treatment with WeGovy for one year and has lost 35 pounds. The provider has recommended WeGovy. The Health Plan indicates that the requested medication is not medically necessary for the treatment of the patient’s medical condition because her body mass index (BMI) is less than 40 without other health problems due to the weight or has a BMI less than 35 with other health problems due to the weight. The issue is whether WeGovy 2.4 mg Auto-injection is medically necessary to treat the patient’s medical condition.
Where the denial was upheld
Physician 1: The patient is a 45-year-old male with a strong family history of coronary artery disease, hyperlipidemia, and prior significant elevated liver function testing. He has been taking Lipitor. The patient has no record of chest discomfort and is currently taking aspirin and exetimibe. A recent stress echo showed no evidence of coronary ischemia. An EBCT scan was performed in August 2004 and the patient has requested reimbursement for the procedure. The Health Plan has denied the patient’s request on the basis that EBCT is considered investigational. Based on the records provided, the patient is asymptomatic with coronary risk factors of strong family history, elevated cholesterol, and a stress test with no ischemia. Guidelines for a coronary risk assessment and treatment have been developed and are continually updated by national expert panels.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Mounjaro auto-injector. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The U.S. Food and Drug Administration (FDA) approved tirzepatide under the brand name Mounjaro in May 2022 for the treatment of patients with type 2 diabetes mellitus. The FDA’s approval was based on the SURPASS-1 clinical trial, which demonstrated that tirzepatide is superior to placebo in improving hemoglobin A1c levels. Subsequent SURPASS clinical trials evaluating the effectiveness of tirzepatide for the treatment of patients with type 2 diabetes also showed great effectiveness in weight reduction. Notably, the SURPASS clinical trials were designed with the primary aim of observing glycemic control.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving hyperlipidemia, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY